Screener
Mirum Pharmaceuticals, Inc. MIRM Business Segments — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:ResearchAndDevelopmentExpenseAcquiredInProcessCost.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 30,348 | 23,421 | 59,153 | 46,439 |
| Research and development | 90,528 | 46,067 | 188,438 | 87,111 |
| Acquired in-process research and development | 16,435 | — | 742,737 | 5,000 |
| Selling, general and administrative | 81,469 | 63,286 | 177,799 | 120,992 |
| Total operating expenses | 218,780 | 132,774 | 1,168,127 | 259,542 |
| Loss from operations | (42,537) | (4,989) | (832,002) | (20,172) |
| Other income (expense): |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s business segments — acquired in-process research and development?
- Mirum Pharmaceuticals, Inc. (MIRM) reported business segments — acquired in-process research and development of $16.44M in Q2 2026.
- What does business segments — acquired in-process research and development mean?
- Represents the value of research and development projects acquired through business combinations that have not yet reached technological feasibility. This metric highlights the company's strategy for inorganic growth and the expansion of its pipeline through external asset acquisition.
Ask your AI about Mirum Pharmaceuticals, Inc.'s business segments — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude